Galapagos NV
GLPG
#4563
Rank
ยฃ1.58 B
Marketcap
ยฃ23.71
Share price
-0.57%
Change (1 day)
12.27%
Change (1 year)

Revenue for Galapagos NV (GLPG)

Revenue in 2025 (TTM): ยฃ0.24 Billion

According to Galapagos NV's latest financial reports the company's current revenue (TTM ) is ยฃ0.24 Billion. In 2024 the company made a revenue of ยฃ0.23 Billion an increase over the revenue in the year 2023 that were of ยฃ96.69 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Galapagos NV from 2015 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) ยฃ0.24 B3.19%
2024 ยฃ0.23 B144.1%
2023 ยฃ96.69 M-77.95%
2022 ยฃ0.43 B5.18%
2021 ยฃ0.41 B4.52%
2020 ยฃ0.39 B-43.67%
2019 ยฃ0.70 B166.98%
2018 ยฃ0.26 B145.85%
2017 ยฃ0.10 B-4.63%
2016 ยฃ0.11 B286.72%
2015 ยฃ29.24 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
AstraZeneca
AZN
ยฃ43.63 B 18,056.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Johnson & Johnson
JNJ
ยฃ69.17 B 28,683.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
ยฃ35.67 B 14,744.74%๐Ÿ‡ซ๐Ÿ‡ท France
AbbVie
ABBV
ยฃ44.77 B 18,530.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Fortress Biotech
FBIO
ยฃ44.51 M-81.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
ยฃ32.91 B 13,594.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ12.59 B 5,140.08%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
GlaxoSmithKline
GSK
ยฃ31.79 B 13,129.14%๐Ÿ‡ฌ๐Ÿ‡ง UK
Merck
MRK
ยฃ48.21 B 19,964.19%๐Ÿ‡บ๐Ÿ‡ธ USA